Invitae Corp (NY: NVTA )
34.14 USD -1.87 (-5.19%) Official Closing Price Updated: 7:59 PM EST, Mar 5, 2021 Add to My Watchlist
Press releases about Invitae Corp
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the Oppenheimer 31st Annual Healthcare Conference on Tuesday,...
Invitae adds Medneon's risk assessment tools to its education and clinical support offerings
February 24, 2021
Invitae expands capabilities of its advanced clinical chatbot Gia, enhancing telemedicine support for patients and clinicians
February 23, 2021
-- Clinicians can now share test results reports with patients directly, reducing delays and need for in-person visits --
Invitae to Present at The Cowen 41st Annual Healthcare Conference
February 22, 2021
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at The Cowen 41st Annual Healthcare Conference on Tuesday, March...
Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020
February 17, 2021
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the 10th Annual SVB Leerink Global Healthcare Conference on...
Invitae to Announce Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 17, 2021
February 03, 2021
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2020 financial results on Wednesday, February 17, 2021 and...
Decibel Therapeutics and Invitae Announce Launch of Amplify™ Genetic Testing Program
January 29, 2021
Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced a partnership...
Invitae Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock and Closing of Underwritten Public Offering
January 26, 2021
Invitae Corporation (NYSE: NVTA) today announced the closing of its underwritten public offering of 8,932,038 shares of its common stock, including 1,165,048 shares sold pursuant to the exercise in...
Invitae Announces Pricing of Public Offering of Common Stock
January 21, 2021
Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to the public of $51.50 per share. All of the shares...
Invitae Announces Proposed Public Offering of Common Stock
January 20, 2021
Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $400.0 million of shares of its common stock, before deducting underwriting discounts and...
Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)
January 14, 2021
-- Project aims to standardize MRD data generation, assessment and accelerate AML clinical trial programs bringing novel therapies to patients in need faster --
Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform
January 13, 2021
New platform expected to make whole genome sequencing significantly more affordable and accessible for use in mainstream medical care
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
January 11, 2021
-- Presenting at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021 at 10:50 a.m. Eastern/7:50 a.m. Pacific --
Invitae to Present at the 39th Annual J.P. Morgan Healthcare Conference
December 29, 2020
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 39th Annual J.P. Morgan...
Invitae Introduces Routine Exome Reanalysis to Help Patients Receive Diagnoses Faster
December 17, 2020
-- Artificial intelligence-powered technology helps bring the benefits of comprehensive clinical sequencing to patient care while maintaining exceptional accuracy and reproducibility --
Invitae to Present New Data Supporting Genetic Testing for All Breast Cancer Patients at the 2020 San Antonio Breast Cancer Symposium
December 09, 2020
Invitae (NYSE: NVTA), a leading medical genetics company, today announced three studies demonstrating the benefits of genetic testing for all breast cancer patients, impacting treatment decisions and...
New Study Highlights the Importance of Genetic Testing for Pancreatic Cancer Patients
November 19, 2020
-- Study finds nearly 1 in 10 show genetic changes with established clinical management recommendations, potential eligibility for precision therapies and/or clinical treatment trials --
Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1
November 09, 2020
Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020
November 05, 2020
Research Highlights Frequency of Genetic Risk Factors Among Men with Prostate Cancer, Suggests Role for Broader Screening
October 28, 2020
Data presented by Invitae (NYSE: NVTA), a leading medical genetics company, at the American Society of Human Genetics (ASHG) Virtual Meeting found one in ten men with prostate cancer harbor genetic...
Invitae to Announce Third Quarter 2020 Financial Results on Thursday, November 5, 2020
October 23, 2020
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020 and will host a...
Invitae and Pacific Biosciences Collaborate to Develop Whole Genome Sequencing-Based Assays for Pediatric Epilepsy Diagnostics
October 22, 2020
New Study Finds Germline Genetic Testing Detects Actionable Findings Missed by Tumor-only Sequencing
October 08, 2020
--Study suggests all cancer patients could benefit from both germline and somatic testing, utility of germline testing in identifying additional treatment options for cancer patients --
Taysha Gene Therapies Partners with Invitae to Enable Rapid Access to Genetic Testing and Earlier Diagnosis of Patients with CNS Disease for Rare and Large-Market Indications
October 06, 2020
Taysha Gene Therapies Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the...
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
October 05, 2020
-- World-class germline and somatic testing, liquid biopsy and tissue genomic profiling, now delivered from a single platform with unrivaled breadth and flexibility --
Invitae Appoints Kimber Lockhart to its Board of Directors
September 11, 2020
-- Brings expertise and leadership in scaling engineering and digital tools throughout her career as a tech entrepreneur --
PTC Therapeutics Launches PTC PINPOINT - A Genetic Testing Program for Individuals Suspected of Having Neurotransmitter Disorders
September 09, 2020
- Early diagnosis through genetic testing may lead to improved long-term outcomes for patients with neurotransmitter disorders, including AADC deficiency -
Multi-site study to evaluate the role of testing guidelines in ensuring access to genetic information for men with prostate cancer
September 03, 2020
Invitae to Participate in the Morgan Stanley Virtual Global Healthcare Conference
September 01, 2020
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will virtually participate in a fireside chat at the 18th Annual Morgan Stanley...